Articles related to ANEMIA
Anemia of Chronic Kidney Disease: Will New Agents Deliver on Their Promise?
A newly developed prolyl hydroxylase inhibitor (agents that increase endogenous erythropoietin production) holds the promise of improving outcomes for patients with anemia of chronic kidney disease. Randomized controlled trials have found these drugs to be at least as effective as erythropoiesis-stimulating agents.
Internal Medicine May 10th 2022
FDA Says No to Vadadustat Approval Due to Safety Concerns
The US Food and Drug Administration (FDA) has said “no” to Akebia Therapeutics’ drug application for vadadustat, a therapy to treat anemia due to chronic kidney disease. Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor designed to mimic the physiologic effect of altitude on oxygen availability. The FDA cited safety concerns as the main reason for it rejecting the application.
Family Medicine/General Practice April 12th 2022
A Bleeding Diathesis in a 65-Year-Old Woman with Newly Diagnosed Breast Cancer
After diagnosis during a partial mastectomy, this patient’s estimated blood loss was 58 mL, causing anemia and requiring a red blood cell transfusion along with ventriculoperitoneal drain placement. With a substantive bleeding history before the diagnosis, what would you do next with this patient? Work her up for von Willebrand disease? Do a complete blood count test to look at platelet count, a peripheral smear to look at the morphology of the platelets, and a coagulation profile? Offer genetic testing for fibrinogen disorders? What would your next steps be? Read the full case presentation and expert opinion to see how your peers responded.
Emergency Medicine August 3rd 2021
How I Treat Warm Autoimmune Hemolytic Anemia
Warm autoimmune hemolytic anemia (wAIHA) is the most prevalent form of autoimmune hemolytic anemia (AIHA), accounting for 60% to 70% of all cases. In this special instructional series from Blood (ASH), five patient case studies and commentaries are examined, backed by visual illustrations and new/existing drug treatment tables for wAIHA, wAIHA secondary to CLL, and R/R wAIHA.
Hematology March 16th 2021
Development of Luspatercept to Treat Ineffective Erythropoiesis
This “Clinical Trials & Observations” report from Blood Advances (ASH) explores the implications of the recently approved anemia treatment luspatercept, which can now be prescribed in the second-line setting after erythropoiesis-stimulating agents (ESAs) have failed or for patients who are not eligible because of high serum erythropoietin (sEPO) levels. A downloadable visual abstract helps paint the picture as well.
Hematology March 16th 2021
Questions and Controversies in Iron-Deficiency Anemia
ASH Clinical News speaks with Maureen Achebe, MD, MPH, Clinical Director of the Non-Malignant Hematology Clinic at Brigham and Women’s Hospital in Boston, and other experts, about the safety and efficacy of IV iron products, how they are perceived in the community, and barriers to their use in the clinic.
Family Medicine/General Practice October 19th 2020